Abstract:Interleukin-12 (IL-12) gene was shown to produce both IL-12 and p40 subunit. The excess production of the p40 subunit as a natural antagonist of IL-12 is a major obstacle of IL-12 gene-based cancer therapy. We previously reported that IL-12N220L gene, which selectively reduces the secretion of the p40 subunit, induces long-lasting stronger type 1 helper T cells (T(H)1) and cytotoxic T lymphocyte (CTL) immunity in hepatitis C virus (HCV) E2 DNA vaccination model and higher protection from challenge with tumor cells expressing E2 than IL-12 in a prophylactic setting. Here, we demonstrated that intratumoral injection of IL-12N220L-expressing adenovirus showed better tumor growth inhibition and higher survival rate than that of IL-12 or granulocyte macrophage-colony stimulating factor (GM-CSF)-expressing adenovirus in a therapeutic setting. In particular, the mice cured by IL-12N220L treatment were protected against intravenous rechallenge of the same tumor cells better than those by IL-12 treatment. In addition, the enhanced antitumor activity of IL-12N220L was confirmed in B16F10 lung metastasis model, which correlated with the frequency of tumor-specific interferon (IFN)-gamma-secreting cells. When tested in CT26/NP tumor that expresses influenza nucleoprotein (NP) as a tumor antigen, IL-12N220L induced stronger NP-specific T(H)1 and CTL responses than IL-12, particularly at a later time point, indicating the generating long-term tumor-specific memory T-cell responses. Moreover, the potent antitumor effects of IL-12N220L were further augmented by combination with chemotherapy using farnesyltransferase inhibitor (FTI), LB42908. Taken together, our results suggest that IL-12N220L is superior to IL-12 in cancer immunotherapy, which can be further enhanced by combination with chemotherapy.

Application of IL-13Rα2-directed Toxin Fusion Protein in Tumor Therapy

Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.

Expression of IL-13Rα2 in Liver Cancer Cells and Its Effect on Targeted Therapy of Liver Cancer

Targeted Killing Effect of IL-13 Diphtheria Toxin Fusion Protein and DT_(389)-hIL13-13E13K

The application of Interleukin-2 family cytokines in tumor immunotherapy research

Interleukin-12 Delivery Strategies and Advances in Tumor Immunotherapy

Progress of IL-12 in Tumor Immunotherapy

Killing Effect Of Interleukin-13 Receptor Alpha 2 (Il-13r Alpha 2) Sensitized Dc-Ctl Cells On Human Glioblastoma U-251 Cells

THE STUDY OF EXPRESSION AND FUNCTION OF ANTIBODY-CYTOKINE FUSION PROTEIN 183B2scfv-Interleukin 2

Antitumor Activities of Interleukin-12 in Melanoma

Expression Of Fusion Il2-B7.1(Igv+C) And Effects On T Lymphocytes

Interleukin 15-Presenting Nanovesicles with Doxorubicin-Loaded Ferritin Cores for Cancer Immunochemotherapy.

Research progress of Interleukin-15 in cancer immunotherapy

Advances in IL-7 Research on Tumour Therapy

Interleukin-13 and Its Receptors in Colorectal Cancer (Review)

Killing effect of interleukin-13 receptor alpha 2 (IL-13Ralpha2) sensitized DC-CTL cells on human glioblastoma U251 cells

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies

Immunotherapy of Metastatic and Autochthonous Liver Cancer with IL-15/IL-15Rα Fusion Protein.

Emerging IL-12-based nanomedicine for cancer therapy

Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor

Tumor-Targeted Delivery of IL-2 by Fusing with a pH Low Insertion Peptide for Antitumor Immunotherapy